Pharm Exec Podcast
1) Pharmaceutical Executive Daily: Merck's $70 Billion Investment
In today’s Pharmaceutical Executive Daily, we cover Merck’s $70 billion expansion of U.S. operations, the FDA’s latest approvals for Novo Nordisk’s Rybelsus and Roche’s Gazyva, and a new digital healt...Show More
2) Pharmaceutical Executive Daily: FDA's National Priority Voucher Program
In today’s Pharmaceutical Executive Daily, we cover the FDA’s creation of a new National Priority Voucher Program, the market reaction to President Trump’s remarks on GLP-1 drug prices, and how autono...Show More
3) Shifting Focus in Autoimmune Diseases
Artax Biopharma’s CEO Rob Armstrong explains recent shifts in autoimmune R&D before discussing his leadership style.
4) Pharmaceutical Executive Daily: EMD Serono’s Agreement with US Government
In today’s Pharmaceutical Executive Daily, we explore how antibody-drug conjugate collaborations are moving beyond oncology into autoimmune diseases, EMD Serono’s agreement with the Trump administrati...Show More
5) Pharmaceutical Executive Daily: Rethinking Workforce Development
In today’s Pharmaceutical Executive Daily, we explore how pharma leaders are rethinking workforce development at the executive level, the industry’s growing investment in rare disease therapies, and e...Show More
6) Pharmaceutical Executive Daily: Johnson & Johnson Separating Its Orthopedics Unit
In today’s Pharmaceutical Executive Daily, we explore Johnson & Johnson’s plan to separate its orthopaedics division into a standalone company, the global implications of the Most Favored Nation drug ...Show More
7) Pharmaceutical Executive Daily: Direct-To-Consumer Trends
In today’s Pharmaceutical Executive Daily, we cover Takeda’s new multi-year research collaboration with Nabla Bio, how tariff and pricing pressures are driving pharma toward direct-to-consumer strateg...Show More
8) Advancing Neuroscience and Rare Disease Innovation
Acadia Pharmaceuticals’ CEO Catherine Owen Adams discusses the current climate in R&D and details her leadership style.
9) Pharmaceutical Executive Daily: Policy Whiplash
In today’s Pharmaceutical Executive Daily, we cover Ypsomed’s new North Carolina manufacturing site, how pharma leaders are maintaining strategic clarity amid policy whiplash, and Excellergy’s $70 mil...Show More
10) Pharmaceutical Executive Daily: Most Favored Nation Order's Evolving Landscape
In today’s Pharmaceutical Executive Daily, we cover Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics, ongoing legal and market implications of the Most Favored Nation drug prici...Show More